Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for ALFRED G. GILMAN
341.51
-3.77 (-1.09%)
Aug 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 341.11 - 347.00
52 week 230.70 - 353.05
Open 347.00
Vol / Avg. 389,668.00/797,718.00
Mkt cap 34.90B
P/E 97.75
Div/yield     -
EPS 3.49
Shares 99.09M
Beta 0.89
Inst. own 75%
Nov 3, 2014
Q3 2014 Regeneron Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 8, 2014
Regeneron Pharmaceuticals Inc at Morgan Stanley Healthcare Conference - 8:45AM EDT - Add to calendar
Sep 4, 2014
Regeneron Pharmaceuticals Inc at Citi Biotech Conference - 10:00AM EDT - Add to calendar
Sep 3, 2014
Regeneron Pharmaceuticals Inc at Robert W. Baird & Co. Inc Health Care Conference - 4:05PM EDT - Add to calendar
Sep 2, 2014
Sanofi SA IR Thematic Call on Alirocumab - 8:30AM EDT - Add to calendar
Aug 5, 2014
Q2 2014 Regeneron Pharmaceuticals Earnings Release
Aug 5, 2014
Q2 2014 Regeneron Pharmaceuticals Inc Earnings Call
Jun 13, 2014
Regeneron Pharmaceuticals Annual Shareholder Meeting
Jun 10, 2014
Regeneron Pharmaceuticals at Goldman Sachs Healthcare Conference
Jun 5, 2014
Regeneron Pharmaceuticals at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 13.93% 20.16%
Operating margin 31.79% 36.11%
EBITD margin - 38.07%
Return on average assets 11.08% 16.87%
Return on average equity 16.24% 26.54%
Employees 2,340 -
CDP Score - -

Address

777 Old Saw Mill River Road
TARRYTOWN, NY 10591
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 84
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 50
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Daniel P. Van Plew Senior Vice President, General Manager - Industrial Operations and Product Supply
Age: 41
Bio & Compensation  - Reuters
Murray A. Goldberg Senior Vice President - Administration, Assistant Secretary
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 57
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Senior Vice President - Research and Development Sciences
Age: 57
Bio & Compensation  - Reuters
Robert J. Terifay Senior Vice President - Commercial
Age: 54
Bio & Compensation  - Reuters
George D. Yancopoulos M.D., Ph.D. Chief Scientific Officer and President - Regeneron Laboratories, Director
Age: 54
Bio & Compensation  - Reuters